Bronchitol is as close to a slam dunk as anything in biotech, although that is a very relative thing. I agree with other posters that either the CEO is really confident or really naive to still quote December quarter on almost the last trading day of November for the LOXL2 partnership. With Boehringer, in the CommSec video, the CEO said that Boehringer was planning for success and is confident. Don't know if they were his exact words, but pretty close. I feel that the PXS mob has been around a bit longer than some of the other small cap Aussie biotechs to be saying such things without substance behind it. In any event, 2 inflection points before Christmas (LOXL-2 and BI). I hope it's Merry Christmas for all us holders.
PXS Price at posting:
26.5¢ Sentiment: Hold Disclosure: Held
